Literature DB >> 30238570

Epigenetic dysregulation in hepatocellular carcinoma: an up-to-date review.

Masato Nakamura1, Tetsuhiro Chiba1, Kengo Kanayama1, Hiroaki Kanzaki1, Tomoko Saito1, Yuko Kusakabe1, Naoya Kato1.   

Abstract

Due to the advances made in research based on next generation sequencers, it is now possible to detect and analyze epigenetic abnormalities associated with cancer. DNA methylation, various histone modifications, chromatin remodeling, and non-coding RNA-associated gene silencing are considered to be transcriptional regulatory mechanisms associated with gene expression changes. The breakdown of this precise regulatory system is involved in the transition to cancer. The important role of epigenetic regulation can be observed from the high rate of genetic mutations and abnormal gene expression leading to a breakdown in epigenetic gene expression regulation seen in hepatocellular carcinoma (HCC). Based on an understanding of epigenomic abnormalities associated with pathological conditions, these findings will lead the way to diagnosis and treatment. In particular, in addition to the fact that there are few choices in terms of extant drug therapies aimed at HCC, there are limits to their antitumor effects. The clinical application of epigenetic therapeutic agents for HCC has only just begun, and future developments are expected.
© 2018 The Japan Society of Hepatology.

Entities:  

Keywords:  DNA methylation; chromatin remodeling; epigenetics; hepatocellular carcinoma; histone modification; non-coding RNA

Year:  2018        PMID: 30238570     DOI: 10.1111/hepr.13250

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  20 in total

1.  Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.

Authors:  Kesang Li; Suying Qian; Mengmeng Huang; Mengjie Chen; Ling Peng; Jianwen Liu; Wen Xu; Jianfen Xu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

2.  Combined screening analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma.

Authors:  Jisen Cao; Ruiqiang Zhang; Ye Zhang; Yijun Wang
Journal:  J Gastrointest Oncol       Date:  2022-02

3.  Hypomethylation status of miR-657 promoter region as biomarker for diagnosis of hepatocellular carcinoma: a retrospective study.

Authors:  Zhaoqi Shi; Peng Luo; Xiaoxiao Fan; Junhai Pan; Lifeng He; Daizhan Zhou; Hui Lin
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

4.  Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression.

Authors:  Wei Zhao; Huanye Mo; Runkun Liu; Tianxiang Chen; Nan Yang; Zhikui Liu
Journal:  Br J Cancer       Date:  2022-03-24       Impact factor: 9.075

5.  Identifying Hepatocellular Carcinoma Driver Genes by Integrative Pathway Crosstalk and Protein Interaction Network.

Authors:  Wenbiao Chen; Jingjing Jiang; Peizhong Peter Wang; Lan Gong; Jianing Chen; Weibo Du; Kefan Bi; Hongyan Diao
Journal:  DNA Cell Biol       Date:  2019-08-29       Impact factor: 3.311

Review 6.  The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review.

Authors:  Bo Hu; Jian-Zhen Lin; Xiao-Bo Yang; Xin-Ting Sang
Journal:  Cell Prolif       Date:  2020-03-11       Impact factor: 6.831

7.  DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma.

Authors:  Junyu Long; Peipei Chen; Jianzhen Lin; Yi Bai; Xu Yang; Jin Bian; Yu Lin; Dongxu Wang; Xiaobo Yang; Yongchang Zheng; Xinting Sang; Haitao Zhao
Journal:  Theranostics       Date:  2019-09-25       Impact factor: 11.556

8.  14-CpG-Based Signature Improves the Prognosis Prediction of Hepatocellular Carcinoma Patients.

Authors:  Hong-Ye Jiang; Gang Ning; Yen-Sheng Wang; Wei-Biao Lv
Journal:  Biomed Res Int       Date:  2020-01-08       Impact factor: 3.411

9.  Histone Methyltransferase G9a-Promoted Progression of Hepatocellular Carcinoma Is Targeted by Liver-Specific Hsa-miR-122.

Authors:  Lan-Ting Yuan; Wei-Jiunn Lee; Yi-Chieh Yang; Bo-Rong Chen; Ching-Yao Yang; Min-Wei Chen; Ji-Qing Chen; Michael Hsiao; Ming-Hsien Chien; Kuo-Tai Hua
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

10.  Identification and validation of the angiogenic genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma.

Authors:  Jinyu Zhu; Bufu Tang; Jie Li; Yueli Shi; Minjiang Chen; Xiuling Lv; Miaomiao Meng; Qiaoyou Weng; Nannan Zhang; Kai Fan; Min Xu; Jiansong Ji
Journal:  Aging (Albany NY)       Date:  2020-05-06       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.